Replimune Group (7R8) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

7R8 Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Replimune

Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

7R8 Stock 12 Month Forecast

Average Price Target

€16.83

▲(30.86% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is €16.83 with a high forecast of €21.10 and a low forecast of €12.31. The average price target represents a 30.86% change from the last price of €12.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","22":"€22","6.25":"€6.25","11.5":"€11.5","16.75":"€16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.0991236,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€21.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.82906287142857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€16.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.3078221,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€12.31</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.25,11.5,16.75,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.745,13.387624892307691,14.030249784615384,14.672874676923076,15.315499569230768,15.95812446153846,16.600749353846155,17.243374246153845,17.885999138461536,18.52862403076923,19.171248923076924,19.813873815384614,20.456498707692305,{"y":21.0991236,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.745,13.059158682417582,13.373317364835163,13.687476047252746,14.001634729670329,14.31579341208791,14.629952094505493,14.944110776923075,15.258269459340656,15.57242814175824,15.886586824175822,16.200745506593403,16.514904189010988,{"y":16.82906287142857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.745,12.71137093076923,12.677741861538461,12.644112792307691,12.610483723076923,12.576854653846153,12.543225584615383,12.509596515384615,12.475967446153845,12.442338376923075,12.408709307692307,12.375080238461537,12.34145116923077,{"y":12.3078221,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.336,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.52,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.625,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.745,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€21.10

Average Price Target€16.83

Lowest Price Target€12.31

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Evan Seigerman

BMO Capital

€17.58

Buy

36.72%

Upside

Reiterated

09/10/26

Analysts Offer Insights on Healthcare Companies: Microbot Medical (NASDAQ: MBOT) and Replimune Group (NASDAQ: REPL)

Unknown Analyst

Kempen & Co

Not Ranked

Kempen & Co

€16.7

Buy

29.89%

Upside

Initiated

09/10/26

Replimune Group (REPL) Receives a Buy from Kempen & Co

Anupam Rama

J.P. Morgan

€17.58→€18.46

Buy

43.56%

Upside

Assigned

08/26/26

Replimune price target raised to $21 from $20 at JPMorganReplimune price target raised to $21 from $20 at JPMorgan

Robert Driscoll

Wedbush

€16.7

Buy

29.89%

Upside

Reiterated

08/17/26

Wedbush Sticks to Its Buy Rating for Replimune Group (REPL)

Roger Song

Jefferies

€21.1

Buy

64.07%

Upside

Reiterated

08/17/26

Jefferies Remains a Buy on Replimune Group (REPL)

Allison Bratzel

Piper Sandler

€12.31

Buy

-4.29%

Downside

Reiterated

08/07/26

Piper Sandler Remains a Buy on Replimune Group (REPL)

Daina Graybosch

Leerink Partners

€9.67→€14.95

Buy

16.21%

Upside

Upgraded

08/03/26

Replimune upgraded to Outperform from Market Perform at LeerinkReplimune upgraded to Outperform from Market Perform at Leerink

Li Watsek

Cantor Fitzgerald

―

Buy

―

Upgraded

07/31/26

Replimune upgraded to Overweight from Neutral at Cantor FitzgeraldReplimune upgraded to Overweight from Neutral at Cantor Fitzgerald

Robert Burns

H.C. Wainwright

―

Sell

―

Downgraded

04/13/26

Replimune downgraded to Sell from Buy at H.C. WainwrightReplimune downgraded to Sell from Buy at H.C. Wainwright

Peter Lawson

Barclays

€2.64

Hold

-79.49%

Downside

Reiterated

10/21/25

Barclays Keeps Their Hold Rating on Replimune Group (REPL)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Evan Seigerman

BMO Capital

€17.58

Buy

36.72%

Upside

Reiterated

09/10/26

Analysts Offer Insights on Healthcare Companies: Microbot Medical (NASDAQ: MBOT) and Replimune Group (NASDAQ: REPL)

Unknown Analyst

Kempen & Co

Not Ranked

Kempen & Co

€16.7

Buy

29.89%

Upside

Initiated

09/10/26

Replimune Group (REPL) Receives a Buy from Kempen & Co

Anupam Rama

J.P. Morgan

€17.58→€18.46

Buy

43.56%

Upside

Assigned

08/26/26

Replimune price target raised to $21 from $20 at JPMorganReplimune price target raised to $21 from $20 at JPMorgan

Robert Driscoll

Wedbush

€16.7

Buy

29.89%

Upside

Reiterated

08/17/26

Wedbush Sticks to Its Buy Rating for Replimune Group (REPL)

Roger Song

Jefferies

€21.1

Buy

64.07%

Upside

Reiterated

08/17/26

Jefferies Remains a Buy on Replimune Group (REPL)

Allison Bratzel

Piper Sandler

€12.31

Buy

-4.29%

Downside

Reiterated

08/07/26

Piper Sandler Remains a Buy on Replimune Group (REPL)

Daina Graybosch

Leerink Partners

€9.67→€14.95

Buy

16.21%

Upside

Upgraded

08/03/26

Replimune upgraded to Outperform from Market Perform at LeerinkReplimune upgraded to Outperform from Market Perform at Leerink

Li Watsek

Cantor Fitzgerald

―

Buy

―

Upgraded

07/31/26

Replimune upgraded to Overweight from Neutral at Cantor FitzgeraldReplimune upgraded to Overweight from Neutral at Cantor Fitzgerald

Robert Burns

H.C. Wainwright

―

Sell

―

Downgraded

04/13/26

Replimune downgraded to Sell from Buy at H.C. WainwrightReplimune downgraded to Sell from Buy at H.C. Wainwright

Peter Lawson

Barclays

€2.64

Hold

-79.49%

Downside

Reiterated

10/21/25

Barclays Keeps Their Hold Rating on Replimune Group (REPL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ONCBeOne Medicines

OVIDOvid Therapeutics

WSTWest Pharmaceutical Services

ZYMEZymeworks

SLDBSolid Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Replimune Group

3 Months

Robert DriscollWedbush

Success Rate

8/16 ratings generated profit

Average Return

-3.83%

Copying Robert Driscoll's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -3.83% per trade.

1 Year

Robert DriscollWedbush

Success Rate

8/16 ratings generated profit

Average Return

+0.52%

Copying Robert Driscoll's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.52% per trade.

2 Years

Roger SongJefferies

Success Rate

5/13 ratings generated profit

Average Return

+32.35%

Copying Roger Song's trades and holding each position for 2 Years would result in 38.46% of your transactions generating a profit, with an average return of +32.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

7R8 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 7R8 has received 15 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 7R8 average Analyst price target in the past 3 months is 16.83.

Each month's total comprises the sum of three months' worth of ratings.

7R8 Financial Forecast

7R8 Earnings Forecast

Next quarter’s earnings estimate for 7R8 is -€0.69 with a range of -€0.75 to -€0.58. The previous quarter’s EPS was -€0.64. 7R8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 7R8 has Performed in-line its overall industry.

No data currently available

7R8 Sales Forecast

Next quarter’s sales forecast for 7R8 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 7R8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 7R8 has Performed in-line its overall industry.

7R8 Stock Forecast FAQ

What is DE:7R8’s average 12-month price target, according to analysts?

Based on analyst ratings, Replimune Group Inc’s 12-month average price target is 16.83.

What is DE:7R8’s upside potential, based on the analysts’ average price target?

Replimune Group Inc has 30.86% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Replimune Group Inc a Buy, Sell or Hold?

Replimune Group Inc has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Replimune Group Inc’s share price target?

The average share price target for Replimune Group Inc is 16.83. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €21.10 ,and the lowest forecast is €12.31. The average share price target represents 30.86% Increase from the current price of €12.86.

What do analysts say about Replimune Group Inc?

Replimune Group Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Replimune Group Inc?

To buy shares of DE:7R8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Replimune Group (7R8) Stock Forecast & Price Target

7R8 Analyst Ratings

7R8 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Replimune Group

7R8 Analyst Recommendation Trends

7R8 Financial Forecast

7R8 Earnings Forecast

7R8 Sales Forecast

7R8 Stock Forecast FAQ

Detailed List of Analyst Forecasts